Tyler Patrick D, Kang Peter M
Cardiovascular Institute, Beth Israel Deaconess Medical Center, 3 Blackfan Circle, CLS 910, Boston, MA 02215.
Curr Pharm Des. 2015;21(42):6070-80. doi: 10.2174/1381612821666151027151957.
Cardiovascular diseases are the major cause of non-communicable illness in both developing and developed nations, representing 30% of global deaths. New therapeutic approaches are desperately needed. Nanomedicine represents one such approach, and involves using molecular entities on the scale of 10-150 nanometers, for purposes of diagnosing, treating, and preventing disease. This review provides a basic overview of nanotechnology, then reviews specific applications of nanotechnology to cardiovascular diseases. Most research has focused on diagnosing and treating atherosclerosis using nanoparticles (NPs). However, researchers are beginning to study NPs for use in acute coronary syndromes, revascularization procedures, and heart failure. Antimicrobial NPs directed at biofilms likely have applicability to identifying and treating endocarditis. Despite the large disease burden of cardiovascular diseases, there are fewer researchers and less funding being applied to this research. Additional investment in NP therapies would pay great dividends once these therapies come of age.
心血管疾病是发展中国家和发达国家非传染性疾病的主要病因，占全球死亡人数的30%。迫切需要新的治疗方法。纳米医学就是这样一种方法，它涉及使用尺寸在10至150纳米范围内的分子实体来诊断、治疗和预防疾病。本文综述首先对纳米技术进行了基本概述，然后回顾了纳米技术在心血管疾病中的具体应用。大多数研究都集中在使用纳米颗粒（NPs）诊断和治疗动脉粥样硬化。然而，研究人员开始研究纳米颗粒在急性冠脉综合征、血管重建手术和心力衰竭中的应用。针对生物膜的抗菌纳米颗粒可能适用于心内膜炎的识别和治疗。尽管心血管疾病的疾病负担很大，但从事这项研究的研究人员较少，资金也较少。一旦这些纳米颗粒疗法成熟，对其进行额外投资将带来巨大回报。
